Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic test accuracies of 4AT items are consistent across the range of baseline cognition: results from two prospective studies.

Age and ageing·2026
Same author

In a prospective population-based study, the degree of mobility impairment during hospitalisation is associated with higher degrees of frailty.

Aging clinical and experimental research·2025
Same author

Persistent delirium is associated with cerebrospinal fluid markers of neuronal injury.

Brain communications·2024
Same author

Delirium, neurofilament light chain, and progressive cognitive impairment: analysis of a prospective Norwegian population-based cohort.

The lancet. Healthy longevity·2023
Same author

Persistent delirium in older hospital patients: an updated systematic review and meta-analysis.

Delirium (Bielefeld, Germany)·2023
Same author

Extremes of baseline cognitive function determine the severity of delirium: a population study.

Brain : a journal of neurology·2023

Related Experiment Video

Updated: May 28, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Multiple sclerosis and pregnancy.

Alex Tsui1, Martin A Lee

  • 1John Radcliffe Hospital, University of Oxford Medical School, Oxford, UK. alex.tsui@doctors.org.uk

Current Opinion in Obstetrics & Gynecology
|October 21, 2011
PubMed
Summary
This summary is machine-generated.

Pregnancy is generally safe for women with multiple sclerosis (MS) and does not worsen the long-term disease course. Treatment decisions during pregnancy should be individualized, and the benefits of breastfeeding for MS relapse rates remain uncertain.

More Related Videos

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Related Experiment Videos

Last Updated: May 28, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

Published on: October 13, 2023

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis
05:55

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

Published on: December 1, 2023

Area of Science:

  • Neurology
  • Immunology
  • Reproductive Medicine

Background:

  • Multiple sclerosis (MS) is a chronic inflammatory neurological disease predominantly affecting women of childbearing age.
  • Managing MS during pregnancy presents unique challenges regarding disease activity and treatment.
  • This review focuses on critical aspects of MS management for pregnant patients.

Purpose of the Study:

  • To review the impact of pregnancy on multiple sclerosis relapse rates and long-term disease progression.
  • To provide updated guidance on using disease-modifying therapies (DMTs) for MS during pregnancy.
  • To outline management strategies for MS relapses and postpartum care, including breastfeeding considerations.

Main Methods:

  • Literature review of studies on pregnancy, multiple sclerosis, and disease-modifying treatments.
  • Analysis of data on relapse rates during pregnancy and postpartum.
  • Evaluation of safety data for MS therapies used around conception and during gestation.

Main Results:

  • Pregnancy is associated with a significant reduction in MS relapse frequency, particularly in the third trimester.
  • A notable increase in relapse risk is observed in the first three months postpartum.
  • Limited negative outcomes were reported for glatiramer acetate and interferon-beta exposure during pregnancy, suggesting treatment continuation possibility.
  • Evidence supporting a protective effect of breastfeeding against MS relapses is inconclusive.

Conclusions:

  • Pregnancy is considered safe for the majority of multiple sclerosis patients and does not adversely affect the overall disease course.
  • The decision to use disease-modifying treatments around conception requires a careful risk-benefit assessment of drug exposure versus relapse risk.
  • The role of breastfeeding in mitigating MS relapses requires further investigation.